发布时间：2025-10-20 10:13 With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%
Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and function
Application for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other markets
Not intended for Canada-, UK- or US-based media



DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objectiv
=*=*=*=*=*=
当前为第1/11页
下一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页